TrialJournal of hematology & oncology2020

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk.

Katja Weisel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.